RESEARCH TRIANGLE PARK, N.C. … Karl Tryggvason, the co-founder of drug development company BioStratum, has been awarded the 2002 Louis-Jeantet Prize for Medicine for his outstanding biomedical research on kidney disease and renal filtration.
The prize, awarded in a ceremony in Geneva, Switzerland, honors each year three scientists who are distinguished for the highest quality of biomedical research in Europe. Winners receive 1.2 million Euros to carry out new research projects.
“On behalf of BioStratum, I would like to congratulate Dr. Tryggvason on receiving the Louis-Jeantet Prize for Medicine. It is an honor for our company to have its co-founder receive such a recognized and prestigious award,” Claus Kuhl, BioStratum’s president and chief executive, says in a statement.
Tryggvason is a world-renowned expert on the molecular genetics of basal lamina disorders, and the basal lamina’s direct involvement in tumor invasion and metastasis. He discovered the alpha 5 and alpha 6 chains of type IV collagen and the gene responsible for the defect in type IV collagen, which gives rise to Alport syndrome, a degenerative kidney
disease. He also is responsible for a breakthrough in the understanding of renal function by isolating the defective gene in congenital nephrotic syndrome, leading to the discovery of the novel protein, nephrin, located at the glomerular slit membrane and essential to renal function.
BioStratum’s lead drug candidate, Pyridorin, is currently advancing through Phase II clinical trials for diabetic kidney disease. Its proprietary anti-cancer drug candidate, Angiocol,
recently received clearance from the U.S. Food and Drug Administration to proceed to Phase I clinical trials.
For further information, visit www.biostratum.com.